UK: Competition Appeal Tribunal Refuses Interim Relief In Pharma Pricing Case

Last Updated: 13 March 2017
Article by Jonathan Parker, Hanna Roos, Hayley M. Pizzey and James Fagan

The Competition Appeal Tribunal (the CAT) in the UK heard on 17 January 2017 an application by Flynn Pharma Ltd and Flynn Pharma (Holdings) Ltd (together Flynn) to suspend the Competition and Markets Authority's (the CMA) direction to reduce the price of an epilepsy drug. The CMA had given the direction as part of its unfair pricing decision in December 2016. In its judgment on 19 January 2017, the CAT dismissed the interim application.

The case is significant because it concerns the first CMA decision on excessive pricing, and a substantial fine of £90 million by the CMA for an alleged abuse of a dominant market position by Flynn and Pfizer Ltd and Pfizer Inc. (together Pfizer). The interim relief judgment also highlights the CAT's focus on the public health impact when assessing the need for interim relief. Flynn and Pfizer are expected to file their appeal of the CMA's December decision by 7 February 2017, and the CAT's determination of their appeal is anticipated later this year.

The CMA's decision and directions

The CMA decided in December 2016 that Flynn and Pfizer had abused their dominant market position in the UK by charging excessive and unfair prices for their epilepsy drug.

The CMA found that Flynn de-branded a prescription drug Epanutin (phenytoin sodium) in September 2012, apparently to avoid the National Health Service's (the NHS) strict rules on how much it can pay for branded drugs, and re-categorised the drug as a generic. The drug was sold by Pfizer to Flynn, and then by Flynn to the NHS.

The CMA's decision alleges that the companies had increased the price by as much as 2,600% in breach of Chapter II of the UK Competition Act 1998 and/or Article 102 of the Treaty on the Functioning of the European Union.

The CMA ordered the companies to pay a fine of £90 million and to reduce their prices for Epanutin. The directions require each of Pfizer and Flynn to implement price reductions within 30 working days of the decision (i.e. by 23 January 2017).

The non-confidential text of the CMA decision has not been published.

The CAT's decision on interim relief

Flynn applied to the CAT for a temporary suspension of the CMA's direction to reduce prices, pending the final outcome of its appeal against the CMA's decision. Pfizer, the CMA and the Department of Health (which triggered the investigation by complaining to the CMA), submitted observations.

The decision considered the five-fold test for interim relief: 1) the prima facie merits of Flynn's case, 2) the need for urgent relief, 3) whether Flynn would suffer significant damage if the relief was not granted, 4) effect on competition and third party interests if the relief was granted, and 5) the balance of interests, taking into account all the relevant circumstances.

The CAT agreed that Flynn had an urgent case which had prima facie merit. It however rejected Flynn's argument that Flynn would be likely to suffer significant damage if interim relief was not granted.

Flynn advanced four main arguments regarding the harm it would suffer by following the directions:

  1. Unworkable directions: The directions are not capable of sensible implementation as they are vague and unworkable, for example because the decision does not specify how much Flynn should reduce its prices by.
  2. Interference in business: The CMA's cost allocation methodology and 6% return on sales (which the CMA considered reasonable) would amount to a gross interference in Flynn's business operations and commercial policy.
  3. Irreversible price reduction: The reduced prices would be likely to be irreversible if Flynn's appeal were to succeed because new competitors will enter the market and it will not be commercially feasible for Flynn to increase prices due to this competition.
  4. Irrevocable reduction in revenue: Implementing the directions would result in an immediate and substantial reduction of revenue. These would be irrecoverable if Flynn were to succeed in its appeal because the CMA did not offer a cross-undertaking in damages.

The CAT considered that the unworkability argument was "significantly weakened" by the fact that Flynn admitted to having a contingency plan for compliance with the price reduction timetable, and that Pfizer had not applied for interim relief and stated that it would (reluctantly) comply with the directions pending hearing of Flynn and Pfizer's appeal. The CAT also felt that Flynn was able to come to its own view on what price would likely be viewed by the CMA as a genuine effort to comply with the decision, and that Flynn had been given some margin for error in setting a new price.

The CAT also viewed the subsequent arguments as "highly speculative". For example, the CAT agreed with Flynn (contrary to the CMA's position) that the loss appeared to have a "significant core" and was irrecoverable in the sense that the CMA offered no compensation. However, the CAT considered that there must be something more than financial loss such as a "demonstrable threat to the applicant's continuation in business". It made reference particularly to Flynn's significant cash reserves, that it would be able to continue to make a return on its costs albeit on a smaller scale than before, and that its financial loss was put into context by the "very substantial benefit" it had obtained from prior sales.

Public health concerns

When considering the last two limbs of the interim relief test, the CAT balanced the perceived harm to the public against the harm to the supplier, and found that public interest concerns weighed more heavily in the balance. It understood harm to the public to mean harm to patients who have been denied funds diverted to purchasing Flynn's product. It considered important that the harm was financial (by limiting the NHS resources available for other conditions), but also non-pecuniary given that patients could not be adequately compensated monetarily in later years for the effects of denied treatment.

The CAT accepted that the case law does not establish that perceived harm to public health will always over-ride the economic interests of businesses, but held that public health may merit special consideration in the hierarchy of interest when weighing up different kinds of harm.

Comment

The CAT's decision is of note because it emphasises that public health – and specifically patient health considerations – can outweigh the financial damage to the supplier.

The decision appears to create a high burden for pharmaceutical companies applying for interim relief going forward. Following the CAT's interpretation, relief requires for example a demonstration of imminent existential threat due to the impact of a competition authority's decision. If a company has in place business contingency plans and generous cash reserves, these might, in light of the CAT's reasoning, weigh against a finding that the company's continuation in business is threatened.

The CAT will make its final determination of the appeal after the parties have completed their submissions.

Meanwhile, the CMA's focus in the pharmaceutical sector is expected to continue. The CMA has opened 12 market investigations during the last two years. A quarter of those relate to the pharma sector, suggesting a relatively intense focus on this market. In addition to pricing scrutiny, the CMA has e.g. issued a fine totalling £45 million in February 2016 against GlaxoSmithKline plc and others for payments and other 'value transfers' which the CMA has characterised as delaying the entry into the UK market of generic versions of the anti-depressant drug paroxetine. The cases appear to be moving through the regulator more quickly than in the past.

This post was prepared with the assistance of Denisa Chytilova and Magdalena Nasuto in the London office of Latham & Watkins.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.